Top Markets
#1 DogBull DogBull +108.52%
#2 MarsCoin MarsCoin +77.08%
#3 Siacoin Siacoin +54.30%
#4 ADO Protocol ADO Protocol +52.57%
#5 The Bitcoin Bull The Bitcoin Bull +28.16%
#6 Ontology Gas Ontology Gas +25.60%
#7 Apertum Apertum +16.37%
#8 Pons Pons +14.02%
#9 Useless Coin Useless Coin +13.13%
#10 Arowana Arowana +12.73%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Rank in Stocks #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Share Price
$4.74
Last synced: 2026-08-31
Market Cap
$372.19M
Change (1 day)
-2.47%
Change (1 year)
-1.04%
Country
US
Trade Lexeo Therapeutics, Inc. Common Stock (LXEO)

Category

Healthcare
Revenue for Lexeo Therapeutics, Inc. Common Stock (LXEO)
Revenue in Sep 2026 TTM: 0
According to Lexeo Therapeutics, Inc. Common Stock latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Lexeo Therapeutics, Inc. Common Stock from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH